CNS Neuroscience & Therapeutics

CNS Neuroscience & Therapeutics (CNS NEUROSCI THER, ISSN: 1755-5930) is a leading international, peer-reviewed journal dedicated to the rapid publication of original research, reviews, and clinical studies in the field of central nervous system (CNS) therapeutics and neuroscience. The journal’s scope encompasses the entire spectrum of CNS drug development and disease management, with a particular emphasis on the translational bridge between basic neurobiology and clinical application. Main topics include, but are not limited to, neurodegenerative disorders (such as Alzheimer’s and Parkinson’s disease), stroke, epilepsy, multiple sclerosis, neuropsychiatric conditions, pain, and neuro-oncology. The journal publishes a diverse array of article types, including original research articles, comprehensive reviews, mini-reviews, editorials, and special themed issues, all of which undergo rigorous single-blind peer review. The primary target audience consists of academic researchers, clinical neurologists, psychiatrists, pharmacologists, and pharmaceutical scientists seeking cutting-edge insights into CNS drug mechanisms, efficacy, and safety. A notable feature of the journal is its open access model, published by Wiley, which ensures that all content is freely and permanently available online, maximizing global dissemination and impact. As of 2026, the journal holds a Journal Citation Reports (JCR) Impact Factor of 6.600, firmly placing it in the Q1 quartile of both the Pharmacology & Pharmacy and Clinical Neurology categories. This standing reflects its strong reputation and high citation influence within the competitive landscape of neuroscience and therapeutic research, making it a premier venue for impactful findings that drive the field forward.